161 related articles for article (PubMed ID: 37708447)
1. In vivo CRISPR screen identifies LTN1 as a novel tumor suppressor ubiquitinating insulin-like growth factor 2 mRNA-binding protein 1 in hepatocellular carcinoma.
Peng R; Cao J; Zhang C; Zhou J; Su BB; Tu DY; Jiang GQ; Jin SJ; Xu YP; Bai DS
Hepatol Commun; 2023 Oct; 7(10):. PubMed ID: 37708447
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide CRISPR knockout screens identify ADAMTSL3 and PTEN genes as suppressors of HCC proliferation and metastasis, respectively.
Zhou X; Li R; Jing R; Zuo B; Zheng Q
J Cancer Res Clin Oncol; 2020 Jun; 146(6):1509-1521. PubMed ID: 32266537
[TBL] [Abstract][Full Text] [Related]
3. Ajuba inhibits hepatocellular carcinoma cell growth via targeting of β-catenin and YAP signaling and is regulated by E3 ligase Hakai through neddylation.
Liu M; Jiang K; Lin G; Liu P; Yan Y; Ye T; Yao G; Barr MP; Liang D; Wang Y; Gong P; Meng S; Piao H
J Exp Clin Cancer Res; 2018 Jul; 37(1):165. PubMed ID: 30041665
[TBL] [Abstract][Full Text] [Related]
4. Tumor necrosis factor α-induced protein 1 as a novel tumor suppressor through selective downregulation of CSNK2B blocks nuclear factor-κB activation in hepatocellular carcinoma.
Xiao Y; Huang S; Qiu F; Ding X; Sun Y; Wei C; Hu X; Wei K; Long S; Xie L; Xun Y; Chen W; Zhang Z; Liu N; Xiang S
EBioMedicine; 2020 Jan; 51():102603. PubMed ID: 31901862
[TBL] [Abstract][Full Text] [Related]
5. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
6. LIN28B-AS1-IGF2BP1 binding promotes hepatocellular carcinoma cell progression.
Zhang J; Hu K; Yang YQ; Wang Y; Zheng YF; Jin Y; Li P; Cheng L
Cell Death Dis; 2020 Sep; 11(9):741. PubMed ID: 32917856
[TBL] [Abstract][Full Text] [Related]
7. miR-625 suppresses tumour migration and invasion by targeting IGF2BP1 in hepatocellular carcinoma.
Zhou X; Zhang CZ; Lu SX; Chen GG; Li LZ; Liu LL; Yi C; Fu J; Hu W; Wen JM; Yun JP
Oncogene; 2015 Feb; 34(8):965-77. PubMed ID: 24632613
[TBL] [Abstract][Full Text] [Related]
8. Genome-wide CRISPR knockout screens identify NCAPG as an essential oncogene for hepatocellular carcinoma tumor growth.
Wang Y; Gao B; Tan PY; Handoko YA; Sekar K; Deivasigamani A; Seshachalam VP; OuYang HY; Shi M; Xie C; Goh BKP; Ooi LL; Man Hui K
FASEB J; 2019 Aug; 33(8):8759-8770. PubMed ID: 31022357
[TBL] [Abstract][Full Text] [Related]
9. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
[TBL] [Abstract][Full Text] [Related]
10. E3 ligase ZFP91 inhibits Hepatocellular Carcinoma Metabolism Reprogramming by regulating PKM splicing.
Chen D; Wang Y; Lu R; Jiang X; Chen X; Meng N; Chen M; Xie S; Yan GR
Theranostics; 2020; 10(19):8558-8572. PubMed ID: 32754263
[No Abstract] [Full Text] [Related]
11. Genome-wide CRISPR screen reveals SGOL1 as a druggable target of sorafenib-treated hepatocellular carcinoma.
Sun W; He B; Yang B; Hu W; Cheng S; Xiao H; Yang Z; Wen X; Zhou L; Xie H; Shen X; Wu J; Zheng S
Lab Invest; 2018 Jun; 98(6):734-744. PubMed ID: 29467456
[TBL] [Abstract][Full Text] [Related]
12. Regulator of Calcineurin 1 Gene Isoform 4, Down-regulated in Hepatocellular Carcinoma, Prevents Proliferation, Migration, and Invasive Activity of Cancer Cells and Metastasis of Orthotopic Tumors by Inhibiting Nuclear Translocation of NFAT1.
Jin H; Wang C; Jin G; Ruan H; Gu D; Wei L; Wang H; Wang N; Arunachalam E; Zhang Y; Deng X; Yang C; Xiong Y; Feng H; Yao M; Fang J; Gu J; Cong W; Qin W
Gastroenterology; 2017 Sep; 153(3):799-811.e33. PubMed ID: 28583823
[TBL] [Abstract][Full Text] [Related]
13. SLFN11 inhibits hepatocellular carcinoma tumorigenesis and metastasis by targeting RPS4X via mTOR pathway.
Zhou C; Liu C; Liu W; Chen W; Yin Y; Li CW; Hsu JL; Sun J; Zhou Q; Li H; Hu B; Fu P; Atyah M; Ma Q; Xu Y; Dong Q; Hung MC; Ren N
Theranostics; 2020; 10(10):4627-4643. PubMed ID: 32292519
[TBL] [Abstract][Full Text] [Related]
14. Fbxw7 is an independent prognostic marker and induces apoptosis and growth arrest by regulating YAP abundance in hepatocellular carcinoma.
Tu K; Yang W; Li C; Zheng X; Lu Z; Guo C; Yao Y; Liu Q
Mol Cancer; 2014 May; 13():110. PubMed ID: 24884509
[TBL] [Abstract][Full Text] [Related]
15. Histone methyltransferase G9a promotes liver cancer development by epigenetic silencing of tumor suppressor gene RARRES3.
Wei L; Chiu DK; Tsang FH; Law CT; Cheng CL; Au SL; Lee JM; Wong CC; Ng IO; Wong CM
J Hepatol; 2017 Oct; 67(4):758-769. PubMed ID: 28532996
[TBL] [Abstract][Full Text] [Related]
16. Jianpi Huayu decoction inhibits the epithelial-mesenchymal transition of hepatocellular carcinoma cells by suppressing exosomal miR-23a-3p/Smad signaling.
Xie CF; Feng KL; Wang JN; Luo R; Fang CK; Zhang Y; Shen CP; Zhong C
J Ethnopharmacol; 2022 Aug; 294():115360. PubMed ID: 35568116
[TBL] [Abstract][Full Text] [Related]
17. Anti-oncogene PTPN13 inactivation by hepatitis B virus X protein counteracts IGF2BP1 to promote hepatocellular carcinoma progression.
Yan Y; Huang P; Mao K; He C; Xu Q; Zhang M; Liu H; Zhou Z; Zhou Q; Zhou Q; Ou B; Liu Q; Lin J; Chen R; Wang J; Zhang J; Xiao Z
Oncogene; 2021 Jan; 40(1):28-45. PubMed ID: 33051595
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) is an important protumorigenic factor in hepatocellular carcinoma.
Gutschner T; Hämmerle M; Pazaitis N; Bley N; Fiskin E; Uckelmann H; Heim A; Groβ M; Hofmann N; Geffers R; Skawran B; Longerich T; Breuhahn K; Schirmacher P; Mühleck B; Hüttelmaier S; Diederichs S
Hepatology; 2014 May; 59(5):1900-11. PubMed ID: 24395596
[TBL] [Abstract][Full Text] [Related]
19. CRISPR/Cas9-mediated knockout of NSD1 suppresses the hepatocellular carcinoma development via the NSD1/H3/Wnt10b signaling pathway.
Zhang S; Zhang F; Chen Q; Wan C; Xiong J; Xu J
J Exp Clin Cancer Res; 2019 Nov; 38(1):467. PubMed ID: 31727171
[TBL] [Abstract][Full Text] [Related]
20. Insulin-Like Growth Factor 1 Receptor Drives Hepatocellular Carcinoma Growth and Invasion by Activating Stat3-Midkine-Stat3 Loop.
Bie C; Chen Y; Tang H; Li Q; Zhong L; Peng X; Shi Y; Lin J; Lai J; Wu S; Tang S
Dig Dis Sci; 2022 Feb; 67(2):569-584. PubMed ID: 33559791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
